|
Poster number |
Title |
Submitting author |
City and Country |
|
107 |
Safety and Efficacy of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MAGNOLIA Phase 2 Study) |
Judith Trotman |
Concord, Australia |
|
108 |
Long term outcomes of gastric MALT lymphoma treated with radiotherapy: a multi-centre retrospective study. |
Clinton Smith |
Randwick, Australia |
|
109 |
Characteristics of Patients Achieving Complete or Partial Response (CR/PR) With Tazemetostat (TAZ) in Wild-Type Relapsed/Refractory (R/R) Follicular Lymphoma (FL) |
Connie Batlevi |
New York, NY, USA |
|
110 |
Atezolizumab + Obinutuzumab + Venetoclax in patients with relapsed or refractory Follicular Lymphoma: primary analysis of a phase 2 trial from LYSA |
Guillaume Cartron |
Montpellier, France |
|
111 |
Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): primary analysis of a Phase 1b/2 trial |
Rajat Bannerji |
New Brunswick, NJ, USA |
|
112 |
CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL) |
Pier Luigi Zinzani |
Bologna, Italy |
|
113 |
Zandelisib, a PI3Kδ Inhibitor on Intermittent Schedule (IS) in Follicular Lymphoma Patients who Progressed within 24 Months of First-Line Chemoimunotherapy (POD24) |
John Pagel |
Seattle, WA, USA |
|
114 |
Outcomes in later-lines of therapy for relapsed/refractory follicular lymphoma: Results from the international SCHOLAR-5 study |
Paola Ghione |
New York, NY, USA |
|
115 |
Outcome of 133 patients with follicular lymphoma (FL) progressing before 24 months (POD24) after immunochemotherapy: a GELTAMO study. |
Ana Muntañola |
Barcelona, Spain |
|
116 |
Bendamustine-Rituximab compared to Rituximab-CHOP/CVP for treatment of patients with indolent lymphoma in Ontario: a population-based study. |
Adam Suleman |
Toronto, Canada |
|
117 |
Maintenance therapy after R-bendamustine vs R‐CHOP in first‐line treatment of low-grade follicular lymphoma: a multicentre, retrospective GELTAMO Study |
Mariana Bastos-Oreiro |
Madrid, Spain |
|
118 |
Obinutuzumab can be administered as a 90-minute short-duration infusion (SDI) in patients with previously untreated follicular lymphoma: GAZELLE end of induction analysis |
Kai Hübel |
Köln, Germany |
|
119 |
UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD-DRIVEN IMMUNOTHERAPY IN EARLY-STAGE FOLLICULAR LYMPHOMA |
Alessandro Pulsoni |
Roma, Italy |
|
120 |
Clinical outcomes and the role of observation in early-stage follicular lymphoma |
Fushen Sha |
New York, NY, USA |
|
121 |
Early metabolic response in Follicular lymphoma: a subset analysis of the FOLL12 trial by the Fondazione Italiana Linfomi (FIL). |
Stefano Luminari |
Reggio Emilia, Italy |
|
122 |
The role of FDG-PET/CT and bone marrow biopsy in detecting bone marrow involvement in the initial staging of follicular lymphoma: an analysis of accuracy and prognostic impact. |
Laura Reguilón Gallego |
Murcia, Spain |
|
123 |
Clinical utility of interim CT scans in patients receiving chemoimmunotherapy for first line treatment of follicular lymphoma |
Farheen Manji |
Toronto, Canada |
|
125 |
Evaluation of four prognostic indexes in first line follicular lymphoma treated with immunochemotherapy. |
Antonio Salar |
Barcelona, Spain |
|
126 |
ANALYSIS OF EZH2 MUTATIONS IN SOLID AND LIQUID BIOPSY AND ITS ROLE AS PREDICTIVE BIOMARKER FOR CHEMOTHERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA |
Mariana Bastos Oreiro |
Madrid, Spain |